bluebird bio, Inc. announced the pricing of its public offering of 20,000,000 shares of common stock at a public offering price of $6.00 per share, with the potential to increase to 23,000,000 shares if the underwriters’ option to purchase additional shares of common stock is exercised. The gross proceeds from the public offering are expected to be $120 million, before deducting underwriting discounts and commissions and offering expenses payable by bluebird. All shares in the offering are to be sold by bluebird, headquartered in Somerville, Massachusetts.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC have come together to lead the way on a new offering. As joint book running managers, they’re poised to make a major impact on the market.
Bluebird Bio is looking to use the funds raised from this offering to further expand and scale its operations. The proceeds will be used to support the commercialization and manufacturing for its two approved gene therapies, ZYNTEGLO and SKYSONA. It will also be used to accelerate the commercialization activities for its gene therapy candidate, lovotibeglogene autotemcel (lovo-cel) for sickle cell disease, if approved. Additionally, the funds will be used to fund working capital and other general corporate purposes.
We anticipate the closing of this offering to take place on or around January 23, 2023, provided all customary closing conditions are met.
The offering is being made under a shelf registration statement that was automatically effective upon filing with the U.S. Securities and Exchange Commission (the “SEC”) on February 18, 2020. A preliminary prospectus supplement outlining the terms of the offering has been filed with the SEC. When available, you can obtain final copies of the prospectus supplement and accompanying prospectus relating to the offering by contacting Goldman Sachs & Co. LLC or J.P. Morgan Securities LLC. Don’t miss out on this opportunity to invest in this offering!
These securities are not for sale in any state or jurisdiction until they have been registered or qualified under the applicable securities laws. Don’t miss out on this opportunity to invest in a unique and potentially lucrative opportunity!
bluebird bio is excited to announce the offering to its investors. This offering, if consummated, could mean big things for the company, from reducing operational expenses to developing our product candidates further. Our forward-looking statements come with inherent risks, such as changes in plans or actual events that may be beyond our control. We are hopeful for the success of our eli-cel, beti-cel, and lovo-cel programs and the ability to bring them to market. We understand that there is no guarantee of success, but we are confident in our ability to develop, approve and commercialize our products and product candidates.